



“OPTIMIZING USE OF RANIBIZUMAB IN THE HOSPITAL PHARMACY: FINANCIAL IMPACT STUDY”



Fernández-Alonso E, Cumbras-Sánchez MJ, Alcácer-López MA, Pardo-Jario MP, Salvador-Gómez T, Merchante-Andreu M.
Hospital Clínico Universitario “Lozano Blesa”, Pharmacy, Zaragoza, Spain

BACKGROUND

In June 2013, it was decided to start a protocol for the use of ranibizumab which was established to group patients in order to fractionate vials in 0.5ml syringes as a saving strategy under aseptic conditions. From each vial, 3 doses of ranibizumab suitable for use are obtained (0.5 mg /0.05ml).

PURPOSE

To evaluate and quantify the economic impact of the optimization vials of ranibizumab.


MATERIAL AND METHODS

Data collected: Patients treated with ranibizumab from June 2012 to May 2013 and compared with patients treated from June 2013 to May 2014, *analyzing the impact provided without such optimization.* Total consumption vials and fractions, number of patients and different diagnoses were analyzed.

Data source: DOMINION® dispensing program

RESULTS


JUNE 2012 – MAY 2013: 240 Patients



Economic impact without fractionation was:

430,462 €

JUNE 2013 – MAY 2014: 400 Patients



Economic impact without fractionation would have been:

1,029,124 €

However, due to fractionation was:

440,336 €

CONCLUSIONS

- The grouping of patients and the fractionation of ranibizumab vials suppose a saving of **588,788€** (714 vials) in one year for the health system.
- The pathology with increased spending on the use of ranibizumab was ARMD exudative, around 90%.